|
Match
|
Document |
Document Title |
|
|
US20070292473 |
DEVICE FOR LOCAL ADMINISTRATION OF SOLID OR SEMI-SOLID FORMULATIONS AND DELAYED-RELEASE FORMULATIONS FOR PROPOSAL PARENTERAL ADMINISTRATION AND PREPARATION PROCESS
A method for implanting or inserting a solid or semisolid formulation containing at least one active principle uses a device comprising one part set inside the body of the patient and which... |
|
|
US20060257359 |
Modifying macrophage phenotype for treatment of disease
The present invention provides compositions and methods for modulating one or more phenotypes of a macrophage-related cell, e.g., a macrophage. The invention further provides methods of treating... |
|
|
US20060263351 |
Methods and compositions for protection against thrombolysis associated reperfusion injury
The invention relates to products and methods for reducing cerebral hemorrhage and edema, which can be negative side-effects of thrombolytic therapies with tissue plasminogen activator (tPA)... |
|
|
US20110028397 |
Use of Urokinase Type Plasminogen Activator Inhibitors for the Treatment of Corneal Disorders
The invention concerns the use of inhibitors of the urokinase type of plasminogen activator (uPA) appearing in the anterior segment of the eye, for the treatment and prevention of corneal ulcers... |
|
|
US20050123507 |
Formulations for coated microprojections having controlled solubility
The invention provides for a formulation for coating one or more microprojections using a non-volatile counterion to improve solubility of a biologically active agent. The invention also includes... |
|
|
US20070293436 |
Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke
The present invention relates generally to the use of γ-glutamyl antioxidants, particularly γ-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic... |
|
|
US20070196272 |
ORAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS
The present invention provides compositions and methods for the administration of the compositions to mammals. The compositions comprise therapeutic agents and an intestinal absorption enhancing... |
|
|
US20050084511 |
Lumen formation-inducible material and instrument to be inserted into the body
The present invention discloses a fistula formation-inducing material having a property of forming a fistula wherein cells are exposed on at least a portion of the fistula luminal surface. This... |
|
|
US20080019910 |
Cancer Treatment and Cancer Treatment Efficacy Prediction by Blocking and Detecting Protease Inhibitors
Disclosed is a method for improving cancer therapy that relies on induction of apoptosis in malignant cells. It has been found that docking of protease inhibitors PAI-1 and TIMP-1 renders... |
|
|
US20060034847 |
Methods of treating a subject for a condition
Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g.,... |
|
|
US20080207508 |
Treatment of Fungal and/or Protist Infections
The present invention relates to the use of a polypeptides, comprising repeats of a peptide derived from a Heparan Sulphate Proteoglycan (HSPG) receptor binding region of an apolipoprotein, for... |
|
|
US20060210532 |
Means and methods for the recruitment and identification of stem cells
Described are methods of modulating stem/progenitor cell recruitment involving molecules that agonize the formation of plasmin stimulating the recruitment of stem/progenitor cells, including... |
|
|
US20090054336 |
Binding Agent
Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents. |
|
|
US20080038361 |
Water-Soluble Nanoparticles Stabilized with Multi-Functional Group Ligands and Method of Preparation Thereof
Disclosed are water-soluble nanoparticles. The water-soluble nanoparticles are each surrounded by a multifunctional group ligand including an adhesive region, a cross linking region, and a... |
|
|
US20070134199 |
Formulation for a protein pharmaceutical without added human serum albumin (HSA)
A composition for stabilization of protein agents in pharmaceuticals, the composition comprising the following two constituents: a) a surface active substance, in particular a non-ionic detergent... |
|
|
US20060002963 |
Use of emulsions for intra and periocular injections
A method for treating eye diseases by injecting intraocularly or periocularly a composition comprising an emulsion and optionally at least a pharmaceutical active ingredient. |
|
|
US20080138277 |
Delivery systems and methods for diagnosing and treating cardiovascular diseases
The invention relates to the treatment and prevention of atherosclerosis and cardiovascular diseases associated with atherosclerosis. The invention further relates to methods of diagnosing... |
|
|
US20050232925 |
Protease activity of thrombin inhibits angiogenesis
The present invention features pharmaceutical compositions and methods to inhibit angiogenesis, with implications to cancer therapy. These methods are based on the discovery that activated... |
|
|
US20090305961 |
Novel chimeric plasminogen activators and their pharmaceutical use
The present invention relates to recombinant chimeric proteins comprising a surfactant protein precursor N-terminally fused to a plasminogen activator or comprising a mature surfactant protein... |
|
|
US20050245444 |
Method of using recombinant human antithrombin for neurocognitive disorders
The present invention provides for the production of recombinant human antithrombin (rhAT) for the treatment or prophylaxis of neurocognitive disorders typically associated with major surgical... |
|
|
US20100210525 |
COMBINED PREPARATION OF A THIAZIDE DIURETIC AND A LOOP DIURETIC
The specific molecular basis of the interaction between talin and integrin β3 has been defined. This specific interaction provides a new therapeutic target; agents that can disrupt this specific... |
|
|
US20080171696 |
Pharmacodynamically enhanced therapeutic proteins
Compositions containing an N-linked oligosaccharide having little or no terminal sialic acid residues which is attached to a therapeutic protein that is bonded to a glycol polymer. |
|
|
US20070196416 |
Pharmaceutical compositions with enhanced stability
The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention... |
|
|
US20070172422 |
Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications
The present invention relates to the compositions, methods, and applications of a new approach to pattern recognition based targeting by which an exponential amplification of effector response can... |
|
|
US20060069035 |
Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA,... |
|
|
US20070141145 |
HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME
The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The... |
|
|
US20090069232 |
GLYCOSYLATION OF MOLECULES
Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered... |
|
|
US20070196269 |
Pharmaceutical composition
The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and/or inducing... |
|
|
US20050158392 |
Lipophilic-coated microparticle containing a protein drug and formulation comprising same
A solid lipophilic microparticle having an average particle size ranging from 0.1 to 200 μm, comprising a lipophilic substance, hyaluronic acid or an inorganic salt thereof and an active... |
|
|
US20070123457 |
Carrier chimeric proteins, targeted carrier chimeric proteins and preparation thereof
A chimeric carrier protein having a multimerization domain and at least one drug attached thereto via a spacer is disclosed. The protein may be targeted by associating at least one amino acid... |